ログインで組織・契約価格をご覧ください。
サイズを選択してください
この商品について
実験式(ヒル表記法):
C8H9FN2O3
CAS番号:
分子量:
200.17
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
EC Number:
241-846-2
MDL number:
製品名
テガフール, ≥98% (HPLC), powder
InChI key
WFWLQNSHRPWKFK-UHFFFAOYSA-N
InChI
1S/C8H9FN2O3/c9-5-4-11(6-2-1-3-14-6)8(13)10-7(5)12/h4,6H,1-3H2,(H,10,12,13)
SMILES string
FC1=CN(C2CCCO2)C(=O)NC1=O
assay
≥98% (HPLC)
form
powder
color
white to off-white
mp
171-173 °C (lit.)
solubility
DMSO: >50 mg/mL
storage temp.
room temp
Quality Level
類似した製品をお探しですか? 訪問 製品比較ガイド
Biochem/physiol Actions
テガフールは、5-フルオロウラシルのプロドラッグであり、抗悪性腫瘍薬として用いられる代謝拮抗薬です。治療として切除された結腸直腸癌療法用のアジュバント化学療法として用いられています。
Application
Tegafur has been used as an internal standard for the analysis of 5′DFCR (5′deoxyfluorocytidine) and 5′DFUR (5′deoxyfluorouridine) using HPLC techniques. Tegafur has also been used as an internal standard for the chromatographic assay of azidothymidine (AZT).
Preparation Note
Tegafur is soluble in DMSO at a concentration that is greater than 50 mg/ml.
signalword
Danger
hcodes
Hazard Classifications
Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral
保管分類
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
適用法令
試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。
T7205-25MG: + T7205-VAR: + T7205-BULK: + T7205-5MG:
jan
Thierry Besnard et al.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 870(1), 117-120 (2008-06-20)
The 5FU prodrug capecitabine undergoes a 3-step enzymatic conversion, including the conversion of 5'DFRC into 5'DFUR by cytidine deaminase (CDA). The presence of CDA activity in blood led us to analyze the possible ex vivo conversion of 5'DFCR into 5'DFUR
Terence C Tang et al.
Neoplasia (New York, N.Y.), 12(3), 264-274 (2010-03-18)
Hepatocellular carcinoma (HCC) is an intrinsically chemotherapy refractory malignancy. Development of effective therapeutic regimens would be facilitated by improved preclinical HCC models. Currently, most models consist of subcutaneous human tumor transplants in immunodeficient mice; however, these do not reproduce the
Muhammad Wasif Saif et al.
Expert opinion on investigational drugs, 18(3), 335-348 (2009-02-27)
S-1 is an oral fluoropyrimidine that is designed to improve the antitumor activity of 5-fluorouracil (5-FU) concomitantly with an intent to reduce its toxicity. S-1 consists of tegafur, a prodrug of 5-FU combined with two 5-FU biochemical modulators:5-chloro-2,4-dihydroxypyridine (gimeracil or
Li-Feng Liu et al.
Chinese medical journal, 125(11), 1931-1935 (2012-08-14)
The pharmacokinetics of zidovudine (AZT) are possibly influenced by weight, age, sex, liver and renal functions, severity of disease, and ethnicity. Currently, little information is available on the steady-state pharmacokinetics of AZT in Chinese HIV-infected patients. The current study aimed
T Yoshimasu et al.
European journal of dermatology : EJD, 11(1), 54-57 (2001-02-15)
A mixture of uracil and tegafur (UFT) is a common antineoplastic agent in Japan. We report a 64-year-old Japanese woman with discoid lupus erythematosus (DLE)-like lesions which were induced by UFT. After surgery to treat lung cancer, UFT (300 mg/day)
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら(テクニカルサービス)